Dimebon attenuates methamphetamine, but not MPTP, striatal dopamine depletion

Neurochemistry International

Volumn 60, Issue 8, 2012, Pages 806-808

  Geldenhuys, Werner J ^a   Darvesh, Altaf S ^a   Dluzen, Dean E ^a,b  

^a NORTHEAST OHIO MEDICAL UNIVERSITY   (United States)

^b Northeastern Ohio Medical University   (United States)

Author keywords

Anti histamine; Body temperature; Neuroprotection; Parkinson's disease

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; ANTIHISTAMINIC AGENT; DIMEBON; DOPAMINE; METHAMPHETAMINE; NEUROTOXIN;

ADOLESCENT; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BODY TEMPERATURE; CONTROLLED STUDY; DOPAMINE BRAIN LEVEL; DOPAMINERGIC SYSTEM; MALE; MOUSE; NEUROPROTECTION; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL;

ANIMALS; CORPUS STRIATUM; DOPAMINE; DRUG SYNERGISM; INDOLES; METHAMPHETAMINE; MICE; MICE, INBRED C57BL;

ANIMALIA; MUS;

EID: 84861141817     PISSN: 01970186     EISSN: 18729754     Source Type: Journal    
DOI: 10.1016/j.neuint.2012.03.013     Document Type: Article

References (19)

1. Bezprozvanny, I., 2010. The rise and fall of Dimebon. Drug News Perspect. 23, 518-523.
2. Bourque, M., Liu, B., Dluzen, D.E., DiPaolo, T., 2011. Sex differences in methamphetamine toxicity in mice: effect on brain dopamine signaling pathways. Psychoneuroendocrinology 36, 955-969.
3. Cadet, J.L., Krasnova, I.N., Jayanthi, S., Lyles, J., 2007. Neurotoxicity of substituted amphetamines: molecular and cellular mechanisms. Neurotox. Res. 11, 183-202.
4. Caudle, W.M., Richardson, J.R., Wang, M.Z., Taylor, T.N., Guillot, T.S., McCormack, A.L., Colebrooke, R.E., Di Monte, D.A., Emson, P.C., Miller, G.W., 2007. Reduced vesicular storage of dopamine causes progressive nigrostriatal neurodegeneration. J. Neurosci. 27, 8138-8148. (Pubitemid 47173329)
5. Fleckenstein, A.E., Volz, T.J., Riddle, E.L., Gibb, J.W., Hanson, G.R., 2007. New insights into the mechanisms of action of amphetamines. Ann. Rev. Pharmacol. Toxicol. 47, 681-698.
6. Geldenhuys, W.J., Van der Schyf, C.J., 2009. The serotonin 5-HT6 receptor: a viable drug target for treating cognitive deficits in Alzheimer's disease. Expert Rev. Neurother. 9, 1073-1085.
7. Grigorev, V.V., Dranyi, O.A., Bachurin, S.O., 2003. Comparative study of action mechanisms of dimebon and memantine on AMPA- and NMDA-subtypes glutamate receptors in rat cerebral neurons. Bull. Exp. Biol. Med. 136, 474-477. (Pubitemid 39137308)
8. Lermontova, N.N., Lukoyanov, N.V., Serkova, T.P., Lukoyanova, E.A., Bachurin, S.O., 2000. Dimebon improves learning in animals with experimental Alzheimer's disease. Bull. Exp. Biol. Med. 129, 544-546.
9. Lermontova, N.N., Redkozubov, A.E., Shevtsova, E.F., Serkova, T.P., Kireeva, E.G., Bachurin, S.O., 2001. Dimebon and tacrine inhibit neurotoxic action of beta-amyloid in culture and block L-type Ca(2+) channels. Bull. Exp. Biol. Med. 132, 1079-1083. (Pubitemid 34295938)
10. Miller, D.B., O'Callaghan, J.P., 1995. The role of temperature, stress and other factors in the neurotoxicity of the substituted amphetamines 3,4- methylenedioxymethamphetamine and fenfluramine. Mol. Neurobiol. 11, 177-192.
11. Naga, K.K., Geddes, J.W., 2011. Dimebon inhibits calcium-induced swelling of rat brain mitochondria but does not alter calcium retention or cytochrome C release. Neuromolecular Med. 13, 31-36.
12. Reinhard Jr., J.F., Diliberto Jr., E.J., Viveros, O.H., Daniels, A.J., 1987. Subcellular compartmentalization of 1-methyl-4-phenylpyridinium with catecholamines in adrenal medullary chromaffin vesicles may explain the lack of toxicity to adrenal chromaffin cells. Proc. Natl. Acad. Sci. USA 84, 8160-8164.
13. Ricaurte, G.A., Langston, J.W., DeLanney, L.E., Irwin, I., Brooks, J.D., 1985. Dopamine uptake blockers protect against the dopamine depleting effect of 1-methyl-4- phenyl-1,2,3,6-tetrahydropyridine (MPTP) in the mouse striatum. Neurosci. Lett. 59, 259-264. (Pubitemid 15235254)
14. Riddle, E.L., Fleckenstein, A.E., Hanson, G.R., 2006. Mechanisms of methamphetamine-induced dopaminergic neurotoxicity. AAPS J. 8, E413-E418. (Pubitemid 43964450)
15. Sabbagh, M.N., Shill, H.A., 2010. Latrepirdine, a potential novel treatment for Alzheimer's disease and Huntington's chorea. Curr. Opin. Invest. Drugs 11, 80-91.
16. Volz, T.J., Hanson, G.R., Fleckenstein, A.E., 2007. The role of the plasmalemmal dopamine and vesicular monoamine transporters in methamphetamine-induced dopaminergic deficiencies. J. Neurochem. 101, 883-888. (Pubitemid 46683868)
17. Wolffgramm, J., Lechner, J., Coper, H., 1988. Interaction of two barbituates and an antihistamine on body temperature and motor performance in mice. Arzneimittelforschung 38, 885-891.
18. Wu, J., Li, Q., Bezprozvanny, I., 2008. Evaluation of Dimebon in cellular model of Huntington's disease. Mol. Neurodegener. 3, 15.
19. Yen, S.Y., Dersch, C., Rothman, R., Cadet, J.L., 1999. Effects of antihistamines on 3,4- methylenedioxymethamphetamine-induced depletion of serotonin. Synapse 33, 207-217. (Pubitemid 29372847)